US › Healthcare

Travere Therapeutics Inc (TVTX)

US · Healthcare · Biotechnology

$56.02+1.89%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$127.2M
Revenue YoY
+55.6%
Net profit
$-37.1M
Profit YoY
+10.0%
EPS
$0.05
EPS estimate
$-0.06
Net margin
-29.2%

EPS came in at 0.05 against a street estimate of -0.06 — a beat of 183.3%.

Key statistics

Market cap
$5.20B
Forward P/E
76.3
P/B
52.64
Book value
$1.07
EPS (TTM)
$-0.50
52-week high
$60.10
52-week low
$15.60
50-day MA
$53.08
200-day MA
$38.36
Beta
1.11

Analyst view

Analysts rate Travere Therapeutics Inc a strong buy (13 buy, 2 hold, 0 sell out of 15) with an average price target of $59.14.

Shareholding

Insiders
0.80%
Institutions
113.77%

Largest institutional holders

FundStake
HHG PLC12.28%
FMR Inc11.79%
BlackRock Inc8.38%
State Street Corp5.33%
Armistice Capital, LLC5.27%
Perceptive Advisors LLC4.45%
Vanguard Capital Management, LLC4.35%
Delaware Management Holdings Inc3.52%

Recent filings & reports

DocumentDate
Board / officer change · Q3 20262026-07-09
Board / officer change · Q2 20262026-06-16
Material agreement · Q2 20262026-06-02
Board / officer change · Q2 20262026-05-21
Quarterly report · Q1 20262026-05-04
Proxy statement · Q2 20262026-04-06
Annual report FY20252026-02-19
Quarterly report · Q3 20252025-10-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Travere Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.